Segment Disclosure

12 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Segment Disclosure

Note 17. Segment Disclosure

The Company has one operating and reporting segment (oncology systems group), which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients. The Company’s Chief Executive Officer, its Chief Operating Decision Maker, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. The Company does not assess the performance of its individual product lines on measures of profit or loss, or asset based metrics. Therefore, the information below is presented only for revenues and long‑lived tangible assets by geographic areas.

Revenues attributed to a country or region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands):

	Years ended June 30,
	2022		2021		2020
Americas	$	126,005	$	105,878	$	128,562
Europe, Middle East, India and Africa		134,640		121,568		119,989
Asia Pacific, excluding Japan and China		28,953		26,425		31,297
Japan		53,376		62,636		72,688
China		86,935		79,782		30,392
Total	$	429,909	$	396,289	$	382,928

Revenues attributed to a country or region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands):

Information regarding geographic areas in which the Company has long‑lived tangible assets is as follows (in thousands):

	June 30, 2022		June 30, 2021
Americas	$	11,251	$	10,588
Europe, Middle East, India and Africa		228		265
Asia Pacific, excluding Japan and China		272		170
Japan		265		701
China		669		608
Total	$	12,685	$	12,332